All News

acr_session2.jpeg

ACR25 Best Abstracts - Day 4

d Jack Cush, MD

Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!

Read Article
RheumNow Podcast square

Halloween ACR Guidance (10.31.25)

d Jack Cush, MD

Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.

Read Article
late breaking

Why I love the late breaking abstracts

d David Liew, FRACP

Every year I love the late breaking abstracts. It’s consistently my favourite part of the meeting program, by some distance. Here's why you should love them, too.

Read Article
question mark

Where are we at with PD-1 agonism?

d David Liew, FRACP

Promising novel mechanisms of action always create excitement, but the immune checkpoint PD-1 has cemented itself in the news far more than most. This fame is primarily from therapeutic inhibition in cancer and rheumatological inflammatory sequelae that emerge, but invoking the inverse and using PD-1 agonism to treat classical autoimmunity has subsequently been making its own mark. Given the evident plausibility, how do we feel about invoking the opposite and agonising PD-1 in classical autoimmunity?

Read Article
bone%20dense.jpg (keep)

Bone Density in Ankylosing Spondylitis

d Bella Mehta, MBBS, MS

Ankylosing spondylitis (AS) is a burden on the bones—both literally and diagnostically. The disease’s dual nature, marked by chronic inflammation and abnormal new bone formation, complicates the assessment of bone health.

Read Article
Upadacitinib is a Double Edged Vascular Sword in GCA Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25. https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D

Links:

Dr. John Cush RheumNow ( View Tweet)
Hospitalization in Stills: Is it "Still" an infection? Dr. Janet Pope discusses abstract 0163, "Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)," https://t.co/3Z0U9XN3nx
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid arthritis and the ‘big bang’ at #ACR25! Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA? https://t.co/QDvdiP3q9R https://t.co/cz4j4vZkSd

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE Conference Preview: progress in biologics at #ACR25 We now have four licensed targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis and belimumab and anifrolumab for active non-renal SLE). What are other issues to be addressed and https://t.co/uvVICAsCzo
Dr. John Cush RheumNow ( View Tweet)
AI Scribes Found their Favorite Doctors Dr. Aurelie Najm discusses abstract 0189, "“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists", presented at #ACR25 https://t.co/QTYFvLa95Y https://t.co/ZIvMovloBL

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Imaging Dr. Arthur Kavanaugh talks about imaging in psoriatic arthritis at #ACR25 https://t.co/l6MKTgEJXu https://t.co/sKhoQWCPli

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE Dr. Sheila Reyes reports on the scientific session presentation of the #ACR25 treatment guidelines for SLE https://t.co/Bh1fSFf8ju https://t.co/OH8h9GDeMf

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day 1 highlights from the 2025 ACR Convergence in Chicago, focusing on abstracts/sessions: 0775, SLE guidelines, 0163, 0832, 0776, 0792, and 0164. https://t.co/ODte4XY82a
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g @synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients. @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X Finally good news in Sjogrens disease. @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

Why are vaccine Abs maintained after CAR-T -depletion of pathogenic #Abs are dampened/eliminated Clonal repetoire expansion Remission=naive B cell pop'n Reset immune system sparing memory cells vs ?not all pathogenic cells eliminated in tissue #ACR25 @RheumNow @ACRheum #26S21 https://t.co/jb3dD5Ssip

Links:

Janet Pope Janetbirdope ( View Tweet)
Day 4 Recap: ACR Convergence 2025 Highlights https://t.co/CMpbzc4O5x Great discussion by @EBRheum @AkhilSoodMD @Dr_Brian_MD . I have always been a FK fan in lupus nephritis as an add on therapy , the only inconvenience is regular monitoring. @RheumNow #ACR25

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)

From Fitbit to first diagnosis: AI is rewriting the RA playbook Two studies presented at this year’s #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://t.co/8AwBZkyZIW
Dr. John Cush RheumNow ( View Tweet)
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases At #ACR25, the ACR presented new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, https://t.co/nJjtTMHnD3
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×